The New York Times analyzes the process whereby Celebrex, an arthritis drug, was promoted by Prizer despite knowing that it was no more effective or safer than other drugs. “Pfizer and its partner. Pharmacia, presented the results from the first six months of a yearlong study rather than the whole thing.” Pfizer defends its decision by saying that 33 million Americans have taken the drug.
Article →
***
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
***
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.
